This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

Internet Monitoring vs Medication to Control Blood Sugar in Type 2 Diabetes

This study is ongoing, but not recruiting participants.
Information provided by (Responsible Party):
ERS Gap Student, Endocrine Research Society Identifier:
First received: July 7, 2014
Last updated: August 17, 2017
Last verified: August 2017
Managing blood sugar levels is important for patients with type 2 diabetes (T2DM) to minimize health problems and complications. One way for patients to notify doctors and receive feedback about their blood sugar management is through an online system. As Internet-based glucose monitoring systems (IBGMS) have already been shown to be effective, the investigators hypothesize that IBGMS is effective as an intervention even when limiting feedback to non-medicine related changes.

Condition Intervention
Type 2 Diabetes Mellitus Other: Internet-Based Glucose Monitoring System Drug: Normal Medication Positive Control

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Supportive Care
Official Title: Investigating if an Internet-Based Glucose Monitoring System is as Effective as Medication at Reducing HbA1c Levels in Type 2 Diabetes Mellitus

Resource links provided by NLM:

Further study details as provided by ERS Gap Student, Endocrine Research Society:

Primary Outcome Measures:
  • HbA1c Levels before and after intervention [ Time Frame: 6 months ]
    Compare HbA1c Levels before and after intervention for both arms, as well as the difference in HbA1c Levels between arms.

Secondary Outcome Measures:
  • The secondary endpoint include severe hypoglycemia defined as requiring external aid (hospital or other). [ Time Frame: 6 months ]
  • A secondary endpoint includes adverse events such as unplanned hospitalizations for any cause that last more than 24 hours [ Time Frame: 6 months ]
  • HbA1c levels remain at 8% or higher [ Time Frame: 3 months ]

Estimated Enrollment: 60
Study Start Date: August 2014
Primary Completion Date: August 2016 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Active Comparator: Internet-Based Glucose Monitoring System
The subjects enrolled in the Internet Therapeutic Intervention arm receive standard care by testing their blood glucose at least 3 times daily and visit the endocrinologist every 3 months; however, they are also asked to upload their blood glucose readings online every 2 weeks for the health practitioner to view and provide feedback limited to non-medicine related comments and suggestions.
Other: Internet-Based Glucose Monitoring System
Other Names:
  • Internet Blood Glucose Monitoring System
  • Remote Blood Glucose Monitoring System
Normal Medication Positive Control
The subjects will be prescribed a new medication as appropriate for normal therapy. This group will receive no biweekly feedback nor require to report online, but will see the endocrinologist every 3 months up to 6 months.
Drug: Normal Medication Positive Control

  Show Detailed Description


Ages Eligible for Study:   18 Years to 80 Years   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Type 2 diabetes patients being treated with oral hypoglycemic agents
  • HbA1c > 8%
  • Willingness to test blood glucose levels a minimum of 3 times daily
  • Willingness to be trained on using the Internet-Based Glucose Monitoring System
  • Willingness to be randomized
  • Trained in self-blood glucose monitoring
  • Internet access on a computer
  • No prior use or training on IBGMS

Exclusion Criteria:

  • Patient with medical conditions that may affect their study participation or results will be excluded.
  • Patients using medications known to influence control of diabetes (eg steroids systemic or inhaled)
  • Liver disease (AST (aspartate aminotransferase) or ALT (alanine aminotransferase) levels > 2.5 times the reference level)
  • Renal insufficient with a serum creatinine level > 200 μmol/L
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT02185755

Canada, British Columbia
Dr. Hugh Tildesley Inc.
Vancouver, British Columbia, Canada, V6E1M7
Sponsors and Collaborators
Endocrine Research Society
Principal Investigator: Hugh D Tildesley, MD Providence Health Care, University of British Columbia
  More Information


Responsible Party: ERS Gap Student, Medical Director, Endocrine Research Society Identifier: NCT02185755     History of Changes
Other Study ID Numbers: IBGMS standalone
Study First Received: July 7, 2014
Last Updated: August 17, 2017

Keywords provided by ERS Gap Student, Endocrine Research Society:
Internet-Based Glucose Monitoring System
Type 2 Diabetes

Additional relevant MeSH terms:
Diabetes Mellitus
Diabetes Mellitus, Type 2
Glucose Metabolism Disorders
Metabolic Diseases
Endocrine System Diseases processed this record on August 23, 2017